Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
- 1 June 2002
- journal article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 1 (1) , 111-118
- https://doi.org/10.1586/14760584.1.1.111
Abstract
The development of adjuvants will represent a major challenge for this century. Indeed the need for safer vaccines leads to the development of a new generation of antigens like synthetic peptide, recombinant proteins or even vectored DNA. However, this is to the detriment of their immunogenicity. The addition of adjuvant is becomes necessary to enhance immune responses and improve vaccine potency. However, adjuvants can be responsible for the apparition of secondary reactions and they must be adapted according to various criteria such as the route of immunization, the type of the immune response, the duration of immunity, or the quality of the antigen, in order to get the best balance between efficacy and safety.Keywords
This publication has 16 references indexed in Scilit:
- Adjuvants designed for veterinary and human vaccinesVaccine, 2001
- Advances in vaccine adjuvantsNature Biotechnology, 1999
- ConferenceVaccine, 1999
- Adjuvants—a classification and review of their modes of actionPublished by Elsevier ,1998
- HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivityAIDS, 1994
- Adjuvants: current status, clinical perspectives and future prospectsImmunology Today, 1993
- Immunomodifiers in VaccinesPublished by Elsevier ,1989
- Vaccine AdjuvantsClinical Infectious Diseases, 1980
- Adjuvants and immune regulation by lymphoid cellsSpringer Seminars in Immunopathology, 1979
- Effect of Adjuvants on Vaccination of Human Beings Against Influenza.Experimental Biology and Medicine, 1945